Wide Field OCTA in Ocular Diseases

The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.

On the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.

The main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age - Related Macular Degeneration (AMD) Best Disease Cardiovascular Diseases Central Serous Chorioretinopathy Central Serous Choroidopathy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Macular Edema Diabetic Retinopathy Embolism and Thrombosis Endocrine System Diseases Eye Diseases Eye Diseases, Hereditary Genetic Diseases, Inborn Geographic Atrophy Inherited Retinal Disease Macular Degeneration Macular Neovascularisation Myopia Ocular Surface Disease Pachychoroid Disease Refractive Errors Retinal Degeneration Retinal Diseases Retinal Dystrophies Retinal Vein Occlusion Retinitis Pigmentosa Retinitis Pigmentosa (RP) Stargardt Disease Thrombosis Uveal Diseases Uveitis Vascular Diseases Venous Thrombosis Vitelliform Macular Dystrophy Vitreoretinal Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Hypothesis: wide field OCT may remarkably contribute on the improvement of diagnostic workup and precision medicine of ocular diseases.

Design: Post-market medical device, monocentric trial. Both cross-sectional and prospective.

The number of study groups and study duration: patients affected by ocular diseases (age-related macular degeneration, diabetic retinopathy, inherited retinal dystrophies, uveitis, myopia, pachychoroid spectrum, dry eye) and healthy controls. Duration 2-years.

the investigators will not expect remarkable biases since our evaluation will be based on the statistical analysis of quantitative imaging metrics coming from the investigational device and the comparator devices.

Both patients and controls will undergo complete ophthalmology assessment and non-invasive imaging diagnostic investigation.

In this study, the investigators will employ one standard-of-care device-Heidelberg Spectralis for retinal imaging and Keratograph 4M for anterior segment evaluation-alongside DreamOCT as the comparator device, replacing the second standard-of-care device typically used in our clinic. This is accepted and agrees with study design since, for diagnostic devices, the procedure to obtain CE approval includes safety check and comparability with other existing devices. Hence, the above described procedure represents the standard of care methodology when testing a novel device in clinical practice.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age > 18 years
Both genders
Confirmed diagnosis of one of the above diseases
Age-related macular degeneration
Diabetic retinopathy
Myopia
Pachychoroid spectrum disease
Inherited retinal dystrophy
Uveitis
Dry eye
Visual acuity of at least 1/20
Signed informed consent for the participation to the trial.

Exclusion criteria

Media opacities
Any other eye or systemic condition that may irreversibly impair the results of the study
Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment

Treatment and study plan

Primary outcomes

Retinal vessel density

Time frame: Cross-sectional investigation at baseline and after 1-year follow-up

Quantitative analysis of macular and peripheral capillary perfusion
Conjunctival vessel density

Time frame: Cross-sectional investigation at baseline and after 1-year follow-up

Conjuctival perfusion in ocular surface diseases

Study contacts

Contact information is provided by the study sponsor or research team.

Alessandro Arrigo, MD, PhD

CONTACT

[email protected]

+390226432648

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Registry information

Official study title

Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.

Acronym: WOOD-2025

Important dates

Study start: 2026
Primary completion: 2028
Study completion: 2028
First posted: Dec 23, 2025
Registry last updated: Dec 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting